Integrative analysis of cancer dependency data and comprehensive phosphoproteomics data revealed the EPHA2-PARD3 axis as a cancer vulnerability in KRAS-mutant colorectal cancer-Reference-Cited by-同舟云学术

Integrative analysis of cancer dependency data and comprehensive phosphoproteomics data revealed the EPHA2-PARD3 axis as a cancer vulnerability in KRAS-mutant colorectal cancer

Published:2023 Issue:8 Volume:19 Page:624-639
ISSN:2515-4184
Container-title:Molecular Omics
language:en
Short-container-title:Mol. Omics

Author:

Gunji Daigo¹²³^ORCID,Narumi Ryohei¹²^ORCID,Muraoka Satoshi¹²⁴^ORCID,Isoyama Junko¹²,Ikemoto Narumi¹²,Ishida Mimiko¹²,Tomonaga Takeshi¹²,Sakai Yoshiharu³^ORCID,Obama Kazutaka³^ORCID,Adachi Jun¹²⁴⁵^ORCID

Affiliation:

1. Laboratory of Proteome Research, National Institute of Biomedical Innovation, Health and Nutrition, Osaka, 567-0085, Japan

2. Laboratory of Proteomics for Drug Discovery, Center for Drug Design Research, National Institute of Biomedical Innovation, Health and Nutrition, Osaka, 567-0085, Japan

3. Department of Surgery, Kyoto University Graduate School of Medicine Faculty of Medicine, Kyoto, 606-8507, Japan

4. Laboratory of Clinical and Analytical Chemistry, Center for Drug Design Research, National Institute of Biomedical Innovation, Health and Nutrition, Osaka, 567-0085, Japan

5. Laboratory of Proteomics and Drug Discovery, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, 606-8501, Japan

Abstract

The phosphoproteomics landscape of 35 CRC cell lines revealed unique molecular characteristics of KRAS-mutant cells.Integrated analysis with gene-dependency data identified vulnerability signals in KRAS-mutant cancers.

Funder

Japan Society for the Promotion of Science

Publisher

Royal Society of Chemistry (RSC)

Subject

Genetics,Molecular Biology,Biochemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2023/MO/D3MO00042G

Reference68 articles.

1. Colorectal cancer

2. NCCN Guidelines Insights: Colon Cancer, Version 2.2018

3. BRAF-Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape

4. First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis

5. Prevalence of ras gene mutations in human colorectal cancers